Replay receives $1.5 million grant for its hypoimmunogenicity Technology Platform
-
Replay developing uCell™, his universal, ready to use, genomically rewritten, source of renewable cells hypoimmunogenic technology, with support from the Bill & Melinda Gates Foundation
-
uCell™ has the potential for democratizatione cell therapy by Okayscathing Cost-goods, facilitate to access at high impact cell therapy some products for underserved communities around the world
-
uCell™ forms part of Replay‘s genomic medicine toolbox this includes a portfolio of potentially disruptive platform technologies, includeing a high payload capacity HSV delivery platform, synHSV™, and a proprietary genome writing platform
-
uCell™ aapplicable to cell therapy across a wide range of therapeutic Regionincluding cancer, Infectious diseases, neurodegenerative diseases, and regenerative medicine
San Diego, California and London, UK, November 28, 2022 – Replay, a genome-writing company that reprograms biology by writing and delivering large DNA, today announced that it has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of ‘uCell™, a proprietary hypoimmunogenic technology platform.
Replay’s uCell™ platform is a ready-to-use, genomically rewritten, hypoimmunogenic technology for silencing allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) immune. The technology is expected to significantly reduce the cost of cell therapy products, improve product volume and consistency, enable in-depth genome engineering and, in the case of cancer cell therapy, enable deeper clinical responses and higher rates. reduced relapse. uCell™ is expected to form the basis of several ready-to-use iPSC-derived immune cell therapies applicable to several therapeutic areas, including cancer and infectious diseases. The technology is relevant to both developed and developing countries, with the expected reduction in the cost of goods improving equity of access.
Adrian WoolfsonExecutive Chairman, President and Co-Freplay sub, commented: “Hypoimmunogenic technology is the ‘holy grail’ of cell therapy and the non-dilutive funding received from the Bill & Melinda Gates Foundation will help accelerate the development of our uCell™ technology. It is expected to address many of the key challenges in cell therapy, including scalability, the ability to introduce large genomic changes, and the need to reduce cost of goods. We are extremely grateful to the foundation and our investors for supporting Replay’s vision for the future of genomic medicine, which emphasizes the development of high-impact, affordable cell therapies accessible to industrialized and rural communities.
Lachlan MacKinnon, President and CEO, and co-Freplay sub, added: “Replay’s hypoimmunogenic technology is the result of a convergence of synthetic biology, computational design and protein engineering with iPS cell technology. This will enable the Company to develop a reliable, scalable and cost-effective plug-and-play universal platform, and expand the utility and accessibility of cell therapy, including regenerative medicine applications. The ability to reprogram hypoimmunogenic iPSCs with our high payload synHSV™ platform will open up a differentiated set of opportunities. As is the case with synHSV™, and given the substantial opportunity in space, we plan to advance our uCell™ technology through separate product companies focused on therapeutic areas.
Professor Hermann forest man, Co-inventor of uCELL™ and Skilled Professor of Pathology at the Sir William Dunn School of Pathology in the University of Oxfordsaid: “As a physician scientist, it is encouraging to see Replay advancing the uCell™ platform, which has the potential to overcome many of the current limitations of cell therapies. By silencing immune iPSCs to generate a universal cell useful as a renewable source for cell therapies, uCell™ has the potential to bring the benefits of this important therapeutic modality to patients worldwide.
Ends
About Proofreading
Replay is a genome writing company, aiming to define the future of genomic medicine by reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic platform and a genome-writing platform – to meet the challenges scientists who are currently limiting clinical progress and preventing genomic medicine from realizing its full potential. The company’s hub-and-spoke business model separates technology development within Replay from therapeutic development within product companies, which leverage technology platforms. For example, Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is used by all four of Replay’s gene therapy product companies, providing great DNA treatments to diseases affecting the skin, eyes, brain, and muscle. The Company has further established an enzyme-writing product company using its scalable inference machine learning and genome-writing technology to optimize functionality. Replay is led by a world-class team of academics, entrepreneurs and industry experts.
The company raised $55 million in seed funding in July 2022 and is backed by an international syndicate of investors that includes KKR, OMX Ventures, ARTIS Ventures and Lansdowne Partners.
Replay is headquartered in San Diego, CA and London, UK. For more information, visit www.replay.bio and follow us on LinkedIn and Twitter.
contacts:
Replay
Dr. Adrian Woolfson/Lachlan MacKinnon
info@replay.bio
The plan Strategic Communications – Media Relations
Amber Fennell/Tracy Cheung/Melissa Gardiner
replay@consilium-comms.com
#Replay #receives #million #grant #hypoimmunogenic #technology #platform